Patents by Inventor Hiroyuki Masayasu

Hiroyuki Masayasu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7671211
    Abstract: A substrate for thioredoxin reductase which comprises a compound represented by the following general formula (I) or (I?): wherein R1 and R2 independently represent a hydrogen atom, a halogen atom, a trifluoromethyl group and the like; R3 represents an aryl group, an aromatic heterocyclic group and the like; R4 represents a hydrogen atom, a hydroxyl group, a —S-?-amino acid group and the like; R5 represents a hydrogen atom or a C1-C6 alkyl group; Y represents oxygen atom or sulfur atom; n represents an integer of from 0 to 5; and the selenium atom may be oxidized, whose example includes 2-phenyl-1,2-benzisoselenazol-3(2H)-one or a ring-opened form thereof. The substrate is reduced by thioredoxin reductase in the presence of NADPH and enhances peroxidase activity of thioredoxin reductase.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: March 2, 2010
    Inventors: Arne Holmgren, Marjan H. Amiri, Hiroyuki Masayasu
  • Patent number: 5948800
    Abstract: The present invention is directed to a drug for preventing or remedying Alzheimer's disease. The drug contains as the active ingredient 2-phenyl-1,2-benzisoselenazol-3(2H)-one (referred as compound (A)), whose effect is based on the action of reducing neuron toxicity induced by .beta.-amyloid protein.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: September 7, 1999
    Assignee: A. Nattermann & Cie. GmbH
    Inventors: Ikuro Maruyama, Kazuhiro Abeyama, Hiroyuki Masayasu
  • Patent number: 5480888
    Abstract: An inhibitor for restenosis after percutaneous coronary arterioplasty, which comprises, as an active ingredient, a compound of the following formula (1), (1') or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 are independently a hydrogen atom, a halogen atom, a trifluoromethyl group, a nitro group, a C1-C6 alkyl group or a C1-C6 alkoxyl group, and R.sup.1 and R.sup.2 may be linked to form a methylenedioxy group; R.sup.3 is an optionally substituted aryl group, an optionally substituted aromatic heterocyclic group, an optionally substituted 5 to 7-membered cycloalkyl or cycloalkenyl group; R.sup.4 is a hydrogen atom, a hydroxyl group, an -S-glutathione residue, an -S-.alpha.-amino acid residue, or an aralkyl group optionally having substituent(s) in the aryl moiety; R.sup.5 is a hydrogen atom or a C1-C6 alkyl group, and R.sup.4 and R.sup.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: January 2, 1996
    Assignee: Daiichi Pharmaceutical Co., Ltd.
    Inventors: Kazuhisa Kodama, Atsushi Hirayama, Hiroyuki Masayasu